Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4

British Journal of Pharmacology

Volumn 172, Issue 13, 2015, Pages 3254-3265

  Milligan, Graeme ^a   Alvarez Curto, E ^a   Watterson, K R ^a   Ulven, T ^b   Hudson, B D ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FASIGLIFAM; G PROTEIN COUPLED RECEPTOR 120; G PROTEIN COUPLED RECEPTOR 40; GLUCOSE; FFAR1 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; LIGAND; O3FAR1 PROTEIN, HUMAN;

CLINICAL STUDY; FUNCTIONAL ASSESSMENT; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; LIGAND BINDING; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVIEW; STRUCTURE ANALYSIS; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETIC VARIATION; GENETICS; METABOLISM;

ANIMALS; GENETIC VARIATION; HUMANS; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84937398931     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12879     Document Type: Review

References (84)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear Hormone Receptors. Br J Pharmacol 170: 1652-1675.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
4. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, et al. (2003). The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 278: 11303-11311.
5. Briscoe CP, Peat AJ, McKeown SC, Corbett DF, Goetz AS, Littleton TR, et al. (2006). Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol 148: 619-628.
6. Burns RN, Singh M, Senatorov IS, Moniri NH, (2014). Mechanisms of homologous and heterologous phosphorylation of FFA receptor 4 (GPR120): GRK6 and PKC mediate phosphorylation of Thr(347), Ser(350), and Ser(357) in the C-terminal tail. Biochem Pharmacol 87: 650-659.
7. Butcher AJ, Hudson BD, Shimpukade B, Alvarez-Curto E, Prihandoko R, Ulven T, et al. (2014). Concomitant action of structural elements and receptor phosphorylation determine arrestin-3 interaction with the free fatty acid receptor FFA4. J Biol Chem 289: 18451-18465.
8. Calder CP, (2013). Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol 75: 645-662.
9. Chen L, Jin L, Zhou N, (2012). An update of novel screening methods for GPCR in drug discovery. Expert Opin Drug Discov 7: 791-806.
10. Christiansen E, Urban C, Merten N, Liebscher K, Karlsen KK, Hamacher A, et al. (2008). Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. J Med Chem 51: 7061-7064.
11. Christiansen E, Due-Hansen ME, Urban C, Merten N, Pfleiderer M, Karlsen KK, et al. (2010). Structure-activity study of para-substituted dihydrocinnamic acids: discovery of the potent and selective FFA1 (GPR40) receptor agonist TUG-469. ACS Med Chem Lett 1: 345-349.
12. Christiansen E, Urban C, Grundmann M, Due-Hansen ME, Hagesaether E, Schmidt J, et al. (2011). Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties. J Med Chem 54: 6691-6703.
13. Christiansen E, Due-Hansen ME, Urban C, Grundmann M, Schröder R, Hudson BD, et al. (2012). Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties. J Med Chem 55: 6624-6628.
14. Christiansen E, Due-Hansen ME, Urban C, Grundmann M, Schmidt J, Hansen SV, et al. (2013a). Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability. J Med Chem 56: 982-992.
15. Christiansen E, Hansen SV, Urban C, Hudson BD, Wargent ET, Grundmann M, et al. (2013b). Discovery of TUG-770: a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes. ACS Med Chem Lett 4: 441-445.
16. Civelli O, Reinscheid RK, Zhang Y, Wang Z, Fredriksson R, Schiöth HB, (2013). G protein-coupled receptor deorphanizations. Ann Rev Pharmacol Toxicol 53: 127-146.
17. Cornish J, MacGibbon A, Lin JM, Watson M, Callon KE, Tong PC, et al. (2008). Modulation of osteoclastogenesis by fatty acids. Endocrinology 149: 5688-5695.
18. Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, et al. (2013). International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev 65: 967-986.
19. Defossa E, Wagner M, (2014). Recent developments in the discovery of GPR40 agonists as novel oral treatment for type 2 diabetes mellitus. Bioorg Med Chem Lett 24: 2991-3000.
20. Dranse HJ, Kelly ME, Hudson BD, (2013). Drugs or diet?-Developing novel therapeutic strategies targeting the free fatty acid family of GPCRs. Br J Pharmacol 170: 696-711.
21. Edfalk S, Steneberg P, Edlund H, (2008). Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57: 2280-2287.
22. Engelstoft MS, Park WM, Sakata I, Kristensen LV, Husted AS, Osborne-Lawrence S, et al. (2013). Seven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells. Mol Metab 4: 376-392.
23. Galindo MM, Voigt N, Stein J, van Lengerich J, Raguse JD, Hofmann T, et al. (2012). G protein-coupled receptors in human fat taste perception. Chem Senses 37: 123-139.
24. Halder S, Kumar S, Sharma R, (2013). The therapeutic potential of GPR120: a patent review. Expert Opin Ther Pat 23: 1581-1590.
25. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, et al. (2005). Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11: 90-94.
26. Hu H, He LY, Gong Z, Li N, Lu YN, Zhai QW, et al. (2009). A novel class of antagonists for the FFAs receptor GPR40. Biochem Biophys Res Commun 390: 557-563.
27. Hudson BD, Smith NJ, Milligan G, (2011). Experimental challenges to targeting poorly characterized GPCRs: uncovering the therapeutic potential for free fatty acid receptors. Adv Pharmacol 62: 175-218.
28. Hudson BD, Shimpukade B, Mackenzie AE, Butcher AJ, Pediani JD, Christiansen E, et al. (2013a). The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol Pharmacol 84: 710-725.
29. Hudson BD, Murdoch H, Milligan G, (2013b). Minireview: the effects of species ortholog and SNP variation on receptors for free fatty acids. Mol Endocrinol 27: 1177-1187.
30. Hudson BD, Shimpukade B, Milligan G, Ulven T, (2014). The molecular basis of ligand interaction at free fatty acid receptor 4 (FFA4/GPR120). J Biol Chem 289: 20345-20538.
31. Humphries PS, Benbow JW, Bonin PD, Boyer D, Doran SD, Frisbie RK, et al. (2009). Synthesis and SAR of 1,2,3,4-tetrahydroisoquinolin-1-ones as novel G-protein-coupled receptor 40 (GPR40) antagonists. Bioorg Med Chem Lett 19: 2400-2403.
32. Ichimura A, Hirasawa A, Poulain-Godefroy O, Bonnefond A, Hara T, Yengo L, et al. (2012). Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 483: 350-354.
33. Im DS, (2012). Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs. Prog Lipid Res 51: 232-237.
34. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, et al. (2003). Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422: 173-176.
35. Kaku K, Araki T, Yoshinaka R, (2013). Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care 36: 245-250.
36. Kantor ED, Lampe JW, Peters U, Vaughan TL, White E, (2014). Long-chain omega-3 polyunsaturated fatty acid intake and risk of colorectal cancer. Nutr Cancer 66: 716-727.
37. Kotarsky K, Nilsson NE, Olde B, Owman C, (2003). Progress in methodology. Improved reporter gene assays used to identify ligands acting on orphan seven-transmembrane receptors. Pharmacol Toxicol 93: 249-258.
38. Kristinsson H, Smith DM, Bergsten P, Sargsyan E, (2013). FFAR1 is involved in both the acute and chronic effects of palmitate on insulin secretion. Endocrinol 154: 4078-4088.
39. Li X, Yu Y, Funk CD, (2013). Cyclooxygenase-2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4). FASEB J 27: 4987-9497.
40. Lin DC, Guo Q, Luo J, Zhang J, Nguyen K, Chen M, et al. (2012). Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol 82: 843-859.
41. Liou AP, Lu X, Sei Y, Zhao X, Pechhold S, Carrero RJ, et al. (2011). The G-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin. Gastroenterology 140: 903-912.
42. Luo J, Swaminath G, Brown SP, Zhang J, Guo Q, Chen M, et al. (2012). A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS ONE 7: e46300.
43. Luttrell LM, Miller WE, (2013). Arrestins as regulators of kinases and phosphatases. Prog Mol Biol Transl Sci 118: 115-147.
44. Mancini AD, Poitout V, (2013). The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends Endocrinol Metab 24: 398-407.
45. Mieczkowska A, Baslé MF, Chappard D, Mabilleau G, (2012). Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. J Biol Chem 287: 23517-23526.
46. Milligan G, Stoddart LA, Smith NJ, (2009). Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. Br J Pharmacol 158: 146-153.
47. Moore K, Zhang Q, Murgolo N, Hosted T, Duffy R, (2009). Cloning, expression, and pharmacological characterization of the GPR120 free fatty acid receptor from cynomolgus monkey: comparison with human GPR120 splice variants. Comp Biochem Physiol B Biochem Mol Biol 154: 419-426.
48. Nakamoto K, Nishinaka T, Sato N, Mankura M, Koyama Y, Kasuya F, et al. (2013). Hypothalamic GPR40 signaling activated by free long chain fatty acids suppresses CFA-induced inflammatory chronic pain. PLoS ONE 8: e81563.
49. Negoro N, Sasaki S, Mikami S, Ito M, Tsujihata Y, Ito R, et al. (2012). Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent. J Med Chem 55: 3960-3974.
50. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. (2010). GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142: 687-698.
51. Paulsen SJ, Larsen LK, Hansen G, Chelur S, Larsen PJ, Vrang N, (2014). Expression of the fatty acid receptor GPR120 in the gut of diet-induced-obese rats and its role in GLP-1 secretion. PLoS ONE 9: e88227.
52. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-1106.
53. Sánchez-Reyes OB, Romero-Ávila MT, Castillo-Badillo JA, Takei Y, Hirasawa A, Tsujimoto G, et al. (2014). Free fatty acids and protein kinase C activation induce GPR120 (free fatty acid receptor 4) phosphorylation. Eur J Pharmacol 723: 368-374.
54. Salehi A, Flodgren E, Nilsson NE, Jimenez-Feltstrom J, Miyazaki J, Owman C, et al. (2005). Free fatty acid receptor 1 (FFA(1)R/GPR40) and its involvement in fatty-acid-stimulated insulin secretion. Cell Tissue Res 322: 207-215.
55. Saltiel AR, (2010). Fishing out a sensor for anti-inflammatory oils. Cell 142: 672-674.
56. Schmidt J, Liebscher K, Merten N, Grundmann M, Mielenz M, Sauerwein H, et al. (2011). Conjugated linoleic acids mediate insulin release through islet G protein-coupled receptor FFA1/GPR40. J Biol Chem 286: 11890-11894.
57. Schröder R, Schmidt J, Blättermann S, Peters L, Janssen N, Grundmann M, et al. (2011). Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat Protoc 6: 1748-1760.
58. Shimpukade B, Hudson BD, Hovgaard CK, Milligan G, Ulven T, (2012). Discovery of a potent and selective GPR120 agonist. J Med Chem 55: 4511-4515.
59. Smith NJ, Stoddart LA, Devine NM, Jenkins L, Milligan G, (2009). The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. J Biol Chem 284: 17527-17539.
60. Srivastava A, Yano J, Hirozane Y, Kefala G, Gruswitz F, Snell G, et al. (2014). High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 513: 124-127.
61. Stoddart LA, Brown AJ, Milligan G, (2007). Uncovering the pharmacology of the G protein-coupled receptor GPR40: high apparent constitutive activity in guanosine 5′-O-(3-[35S]thio)triphosphate binding studies reflects binding of an endogenous agonist. Mol Pharmacol 71: 994-1005.
62. Stoddart LA, Smith NJ, Milligan G, (2008). International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol Rev 60: 405-417.
63. Stone VM, Dhayal S, Brocklehurst KJ, Lenaghan C, Sörhede Winzell M, Hammar M, et al. (2014). GPR120 (FFAR4) is preferentially expressed in pancreatic delta cells and regulates somatostatin secretion from murine islets of Langerhans. Diabetologia 57: 1182-1191.
64. Suckow AT, Polidori D, Yan W, Chon S, Ying Ma J, Leonard J, et al. (2014). Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role for GPR120 in glucagon secretion. J Biol Chem 289: 15751-15763.
65. Sum CS, Tikhonova IG, Neumann S, Engel S, Raaka BM, Costanzi S, et al. (2007). Identification of residues important for agonist recognition and activation in GPR40. J Biol Chem 282: 29248-29255.
66. Sun P, Wang T, Zhou Y, Liu H, Jiang H, Zhu W, et al. (2013). DC260126: a small-molecule antagonist of GPR40 that protects against pancreatic β-cells dysfunction in db/db mice. PLoS ONE 8: e66744.
67. Sun Q, Hirasawa A, Hara T, Kimura I, Adachi T, Awaji T, et al. (2010). Structure-activity relationships of GPR120 agonists based on a docking simulation. Mol Pharmacol 78: 804-810.
68. Suzuki T, Igari S, Hirasawa A, Hata M, Ishiguro M, Fujieda H, et al. (2008). Identification of G protein-coupled receptor 120-selective agonists derived from PPARgamma agonists. J Med Chem 51: 7640-7644.
69. Talukdar S, Olefsky JM, Osborn O, (2011). Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol Sci 32: 543-550.
70. Tanaka H, Yoshida S, Oshima H, Minoura H, Negoro K, Yamazaki T, et al. (2013). Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion. J Pharmacol Exp Ther 346: 443-452.
71. Taneera J, Lang S, Sharma A, Fadista J, Zhou Y, Ahlqvist E, et al. (2012). A systems genetics approach identifies genes and pathways for type 2 diabetes in human islets. Cell Metab 16: 122-134.
72. Tikhonova IG, Sum CS, Neumann S, Thomas CJ, Raaka BM, Costanzi S, et al. (2007). Bidirectional, iterative approach to the structural delineation of the functional 'chemoprint' in GPR40 for agonist recognition. J Med Chem 50: 2981-2989.
73. Tikhonova IG, Sum CS, Neumann S, Engel S, Raaka BM, Costanzi S, et al. (2008). Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. J Med Chem 51: 625-633.
74. Urban C, Hamacher A, Partke HJ, Roden M, Schinner S, Christiansen E, et al. (2013). In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469. Naunyn Schmiedebergs Arch Pharmacol 386: 1021-1030.
75. Waguri T, Goda T, Kasezawa N, Yamakawa-Kobayashi K, (2013). The combined effects of genetic variations in the GPR120 gene and dietary fat intake on obesity risk. Biomed Res 34: 69-74.
76. Watson SJ, Brown AJ, Holliday ND, (2012). Differential signaling by splice variants of the human free fatty acid receptor GPR120. Mol Pharmacol 81: 631-642.
77. Wauquier F, Philippe C, Léotoing L, Mercier S, Davicco MJ, Lebecque P, et al. (2013). The free fatty acid receptor G protein-coupled receptor 40 (GPR40) protects from bone loss through inhibition of osteoclast differentiation. J Biol Chem 288: 6542-6551.
78. Wu P, Yang L, Shen X, (2010). The relationship between GPR40 and lipotoxicity of the pancreatic β-cells as well as the effect of pioglitazone. Biochem Biophys Res Commun 403: 36-39.
79. Wu Q, Wang H, Zhao X, Shi Y, Jin M, Wan B, et al. (2013). Identification of G-protein-coupled receptor 120 as a tumor-promoting receptor that induces angiogenesis and migration in human colorectal carcinoma. Oncogene 32: 5541-5550.
80. Yabuki C, Komatsu H, Tsujihata Y, Maeda R, Ito R, Matsuda-Nagasumi K, et al. (2013). A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS ONE 8: e76280.
81. Yamashima T, (2012). PUFA-GPR40-CREB signaling' hypothesis for the adult primate neurogenesis. Prog Lipid Res 51: 221-231.
82. Yoshida M, Miyazato M, Kangawa K, (2012). Orphan GPCRs and methods for identifying their ligands. Methods Enzymol 514: 33-44.
83. Zamarbide M, Etayo-Labiano I, Ricobaraza A, Martínez-Pinilla E, Aymerich MS, Luis Lanciego J, et al. (2014). GPR40 activation leads to CREB and ERK phosphorylation in primary cultures of neurons from the mouse CNS and in human neuroblastoma cells. Hippocampus 24: 733-739.
84. Zhou C, Tang C, Chang E, Ge M, Lin S, Cline E, et al. (2010). Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists. Bioorg Med Chem Lett 20: 1298-1301.